The Role of MicroRNAs in the Chemoresistance of Breast Cancer

Drug Development Research

Volumn 76, Issue 7, 2015, Pages 368-374

  Wang, Jing ^a   Yang, Muyi ^b   Li, Yu ^c   Han, Bo ^b,d  

^a Fourth People's Hospital of Jinan   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Shandong Provincial Military Command ^*  (China)

^d SHANDONG UNIVERSITY   (China)

Author keywords

breast cancer; chemoresistance; microRNAs

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; MICRORNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; REACTIVE OXYGEN METABOLITE;

3' UNTRANSLATED REGION; APOPTOSIS; BIOGENESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STEM CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CHEMOSENSITIVITY; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DRUG TRANSPORT; EPITHELIAL MESENCHYMAL TRANSITION; HISTONE MODIFICATION; HOMOLOGOUS RECOMBINATION; HUMAN; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MOLECULARLY TARGETED THERAPY;

BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY;

EID: 84945447659     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21275     Document Type: Review

References (35)

1. Bai WD, Ye XM, Zhang MY, Zhu HY, Xi WJ, Huang X, Zhao J, Gu B, Zheng GX, Yang AG, et al., 2014. MiR-200c suppresses TGF-beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int J Cancer 135: 1356-1368.
2. Bartel DP., 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
3. Bartel DP., 2009. MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
4. Betel D, Wilson M, Gabow A, Marks DS, Sander C., 2008. The microRNA.org resource: targets and expression. Nucleic Acids Res 36: D149-D153 (Database issue).
5. Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV., 2010. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst 102: 1637-1652.
6. Cancer Genome Atlas N., 2012. Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
7. Chuthapisith S, Eremin J, El-Sheemey M, Eremin O., 2010. Breast cancer chemoresistance: emerging importance of cancer stem cells. Surg Oncol 19: 27-32.
8. Cleator S, Parton M, Dowsett M., 2002. The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer 9: 183-195.
9. Eroles P, Tormo E, Pineda B, Espin E, Lluch A., 2015. MicroRNAs in breast cancer: one more turn in regulation. Curr Drug Targets. 2015 Feb 12. [Epub ahead of print].
10. Freres P, Josse C, Bovy N, Boukerroucha M, Struman I, Bours V, Jerusalem G., 2014. Neoadjuvant chemotherapy in breast cancer patients induces miR-34a and miR-122 expression. J Cell Physiol 230: 473-481.
11. Garofalo M, Croce CM., 2013. MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat 16: 47-59.
12. Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL, et al., 2014. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget 5: 1174-1184.
13. He DX, Gu XT, Li YR, Jiang L, Jin J, Ma X., 2014. Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer. FEBS J 281: 4718-4730.
14. Jiang L, He D, Yang D, Chen Z, Pan Q, Mao A, Cai Y, Li X, Xing H, Shi M, et al., 2014. MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway. FEBS Lett 588: 2009-2015.
15. Juliano RL, Ling V., 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162.
16. Knezevic J, Pfefferle AD, Petrovic I, Greene SB, Perou CM, Rosen JM., 2015. Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential. Oncogene. 2015 Mar 9. doi: 10.1038/onc.2015.48 [Epub ahead of print].
17. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, Pogribny IP., 2008. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7: 2152-2159.
18. Kutanzi KR, Yurchenko OV, Beland FA, Checkhun VF, Pogribny IP., 2011. MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics 2: 171-185.
19. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, et al., 2003. The nuclear RNase III Drosha initiates microRNA processing. Nature 425: 415-419.
20. Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, Wagar N, Yoon Y, Cho HT, Scala S, et al., 2010. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 79: 817-824.
21. Ma MT, He M, Wang Y, Jiao XY, Zhao L, Bai XF, Yu ZJ, Wu HZ, Sun ML, Song ZG, et al., 2013. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Lett 339: 107-115.
22. Mitra A, Mishra L, Li S., 2015. EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget 6: 10697-10711.
23. Nagata S., 1999. Fas ligand-induced apoptosis. Annu Rev Genet 33: 29-55.
24. Okuda H, Xing F, Pandey PR, Sharma S, Watabe M, Pai SK, Mo YY, Iiizumi-Gairani M, Hirota S, Liu Y, et al., 2013. miR-7 suppresses brain metastasis of breast cancer stem-like cells by modulating KLF4. Cancer Res 73: 1434-1444.
25. Park EY, Chang E, Lee EJ, Lee HW, Kang HG, Chun KH, Woo YM, Kong HK, Ko JY, Suzuki H, et al., 2014. Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res 74: 7573-7582.
26. Pinto CA, Widodo E, Waltham M, Thompson EW., 2013. Breast cancer stem cells and epithelial mesenchymal plasticity-implications for chemoresistance. Cancer Lett 341: 56-62.
27. Sasaki A, Tsunoda Y, Tsuji M, Udaka Y, Oyamada H, Tsuchiya H, Oguchi K., 2014. Decreased miR-206 expression in BRCA1 wild-type triple-negative breast cancer cells after concomitant treatment with gemcitabine and a Poly(ADP-ribose) polymerase-1 inhibitor. Anticancer Res 34: 4893-4897.
28. Serguienko A, Grad I, Wennerstrom AB, Meza-Zepeda LA, Thiede B, Stratford EW, Myklebost O, Munthe E., 2015. Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA. Oncotarget 6: 2451-2465.
29. Takahashi RU, Miyazaki H, Ochiya T., 2015. The roles of microRNAs in breast cancer. Cancers (Basel) 7: 598-616.
30. Videira M, Reis RL, Brito MA., 2014. Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance. Biochim Biophys Acta 1846: 312-325.
31. Wu Q, Yang Z, Nie Y, Shi Y, Fan D., 2014. Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett 347: 159-166.
32. Xue J, Chi Y, Chen Y, Huang S, Ye X, Niu J, Wang W, Pfeffer LM, Shao ZM, Wu ZH, et al., 2015. MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity. Oncogene. 2015 Apr 13. doi: 10.1038/onc.2015.96. [Epub ahead of print].
33. Yang Q, Wang Y, Lu X, Zhao Z, Zhu L, Chen S, Wu Q, Chen C, Wang Z., 2015. MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells. Oncotarget 6: 3268-3279.
34. Youle RJ, Strasser A., 2008. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59.
35. Zhao L, Gu H, Chang J, Wu J, Wang D, Chen S, Yang X, Qian B., 2014. MicroRNA-383 regulates the apoptosis of tumor cells through targeting Gadd45g. PLoS One 9: e110472.